利干德制药 LGND
$306.20 +$7.20 (+2.41%)
休市 · Nov 6, 10:00 pm ET · 最新盘后价 $308.00 +0.59%
开盘$302.02
昨收$299.00
当日区间$297.84 – $308.26
成交量133.0K
市值$6.12B
市盈率（TTM）123.0
股息率–
财报
财报日平均波动±5.8%近16次财报
收涨次数11 / 1669% 的概率
最佳反应+19.9%
最差反应-9.6%
每次财报后次日股价变动
| 季度 | 财报日期 | 时段 | 隐含波动 | 实际波动 | 较隐含波动 |
|---|---|---|---|---|---|
| 2026/Q3 | 29 Oct 2026 | Pre Market | ±7.5% | -0.45% | 符合区间 |
| 2026/Q2 | 6 Aug 2026 | Pre Market | ±7.0% | -0.80% | 符合区间 |
| 2026/Q1 | 7 May 2026 | Pre Market | ±6.3% | -9.55% | 超出定价预期 |
| 2025/Q4 | 26 Feb 2026 | Pre Market | ±8.1% | +2.50% | 符合区间 |
| 2025/Q3 | 6 Nov 2025 | Pre Market | ±5.7% | +9.37% | 超出定价预期 |
| 2025/Q2 | 7 Aug 2025 | Pre Market | ±7.2% | +2.75% | 符合区间 |
| 2025/Q1 | 8 May 2025 | Pre Market | ±11.7% | -2.94% | 符合区间 |
| 2024/Q4 | 27 Feb 2025 | Pre Market | ±10.2% | +0.57% | 符合区间 |
| 2024/Q3 | 7 Nov 2024 | Pre Market | ±9.2% | +11.12% | 超出定价预期 |
| 2024/Q2 | 6 Aug 2024 | After Market | ±9.5% | -5.78% | 符合区间 |
| 2024/Q1 | 7 May 2024 | After Market | ±9.6% | +9.75% | 超出定价预期 |
| 2023/Q4 | 27 Feb 2024 | Pre Market | ±8.2% | +19.86% | 超出定价预期 |
| 2023/Q3 | 8 Nov 2023 | After Market | ±12.0% | +4.61% | 符合区间 |
| 2023/Q2 | 8 Aug 2023 | After Market | ±8.1% | +5.35% | 符合区间 |
| 2023/Q1 | 4 May 2023 | After Market | ±11.5% | +3.42% | 符合区间 |
| 2022/Q4 | 22 Feb 2023 | After Market | ±13.8% | +4.12% | 符合区间 |
"隐含波动"指财报发布前期权市场定价的预期波幅。"波动"指财报发布后首个交易日的股价变化。
基本面
最新报告季度：Q3, ended Sep 2026
营收$78.75M-31.8% YoY
营业利润-$9.49M-117.5% YoY
净利润-$28.49M-124.3% YoY
摊薄每股收益-$1.43-125.2% YoY
自由现金流$21.35M+37.0% YoY
经营现金流$24.02M
营收，近8个季度
净利润，近8个季度
盈利能力与资产负债表
毛利率95.2%
营业利润率14.4%
净利率20.3%
净资产收益率5.4%
资产收益率2.8%
投入资本回报率1.9%
流动比率16.92
负债/资产比率57.0%
现金及投资$447.40M
总负债$1.13B
净现金（净负债）-$680.82M
暂无评论——快来第一个聊聊 LGND。
登录后参与讨论。